{"transactions":[{"id":701398,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-29T20:06:43.000Z","date":"2026-07-29","kind":"sale","planned":false,"acquired":false,"shares":21217,"price":33.4704,"value":710141.4768,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":212204,"source":{"system":"sec-edgar","filing":"0001193125-26-324447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526324447/ownership.xml","form_type":"4"}},{"id":701397,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-29T20:06:43.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan"}],"balance_after":233421,"source":{"system":"sec-edgar","filing":"0001193125-26-324447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526324447/ownership.xml","form_type":"4"}},{"id":950706,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":91000,"derivative":{"exercise_price":35.42,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950705,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":1500,"price":32.0887,"value":48133.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":189891,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950704,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10300,"price":34.2364,"value":352634.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":191371,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950703,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":13900,"price":33.3828,"value":464020.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":201671,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950702,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":31961,"price":32.295,"value":1032180.495,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":215571,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950701,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":32049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal."}],"balance_after":247532,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950700,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 104 shares acquired on May 20, 2025 and 787 shares acquired on November 20, 2025 pursuant to the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":215483,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":1012522,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:47:49.000Z","date":"2025-10-28","kind":"sale","planned":false,"acquired":false,"shares":6185,"price":35.0009,"value":216480.5665,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.6525 to $35.3939, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":173592,"source":{"system":"sec-edgar","filing":"0001193125-25-254298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312525254298/ownership.xml","form_type":"4"}},{"id":1012521,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:47:49.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":11117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal."}],"balance_after":179777,"source":{"system":"sec-edgar","filing":"0001193125-25-254298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312525254298/ownership.xml","form_type":"4"}},{"id":1092089,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T15:31:07.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":4266,"price":27.761,"value":118428.426,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.72 to $27.785, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":168660,"source":{"system":"sec-edgar","filing":"0000950170-25-093792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025093792/ownership.xml","form_type":"4"}},{"id":1092088,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T15:31:07.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":7667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":172926,"source":{"system":"sec-edgar","filing":"0000950170-25-093792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025093792/ownership.xml","form_type":"4"}},{"id":1310144,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":37200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":37200,"derivative":{"exercise_price":42.89,"exercise_date":"2026-01-03","expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":37200},"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310143,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":4700,"price":43.3194,"value":203601.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":165259,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310142,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":45609,"price":42.6888,"value":1946993.4792,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":169959,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310141,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":21667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":215568,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310140,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":44533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2 shares acquired on November 20, 2024 pursuant to the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":193901,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1380603,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"25% of the shares subject to the option vested or will vest on each anniversary of the grant date."}],"balance_after":153000,"derivative":{"exercise_price":8.52,"exercise_date":"2024-01-03","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380602,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-third of the shares subject to the option vested on each anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380601,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":4251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the shares subject to the option vested on each anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":4.68,"exercise_date":"2021-03-31","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":4251},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380600,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the shares subject to the option vested on each anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":7.77,"exercise_date":"2021-01-03","expiration_date":"2030-01-03","underlying":"Common Stock","underlying_shares":12750},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380599,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":1206,"price":81.4447,"value":98222.3082,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.35 to $81.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":149366,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380598,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":7967,"price":80.6508,"value":642544.9236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.30 to $81.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":150572,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380597,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":6050,"price":79.7793,"value":482664.765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.29 to $80.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":158539,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380596,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":15825,"price":78.6907,"value":1245280.3275,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $79.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":164589,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380595,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":23082,"price":77.6804,"value":1793018.9928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":180414,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380594,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":9265,"price":76.935,"value":712802.775,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.27 to $77.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":203496,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380593,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":18620,"price":75.786,"value":1411135.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":212761,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380592,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":49672,"price":74.559,"value":3703494.648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.24 to $75.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":231381,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380591,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":true,"shares":51000,"price":8.52,"value":434520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."}],"balance_after":281053,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380590,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":true,"shares":26000,"price":5.8,"value":150800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."}],"balance_after":230053,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380589,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":true,"shares":4251,"price":4.68,"value":19894.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."}],"balance_after":204053,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380588,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":true,"shares":12750,"price":7.77,"value":99067.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."}],"balance_after":199802,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1445181,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-07-31T16:05:09.000Z","date":"2024-07-30","kind":"sale","planned":false,"acquired":false,"shares":500,"price":58.71,"value":29355.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $58.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":187052,"source":{"system":"sec-edgar","filing":"0000950170-24-088538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024088538/ownership.xml","form_type":"4"}},{"id":1445180,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-07-31T16:05:09.000Z","date":"2024-07-30","kind":"sale","planned":false,"acquired":false,"shares":2974,"price":57.71,"value":171629.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":187552,"source":{"system":"sec-edgar","filing":"0000950170-24-088538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024088538/ownership.xml","form_type":"4"}},{"id":1445179,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-07-31T16:05:09.000Z","date":"2024-07-30","kind":"sale","planned":false,"acquired":false,"shares":12662,"price":56.96,"value":721227.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":190526,"source":{"system":"sec-edgar","filing":"0000950170-24-088538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024088538/ownership.xml","form_type":"4"}},{"id":1445178,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-07-31T16:05:09.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":21667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal."}],"balance_after":203188,"source":{"system":"sec-edgar","filing":"0000950170-24-088538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024088538/ownership.xml","form_type":"4"}},{"id":1445177,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-07-31T16:05:09.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal."}],"balance_after":181521,"source":{"system":"sec-edgar","filing":"0000950170-24-088538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024088538/ownership.xml","form_type":"4"}},{"id":1527778,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":60000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527777,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"exercise","planned":true,"acquired":false,"shares":4249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":4251,"derivative":{"exercise_price":4.68,"exercise_date":"2021-03-31","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":4249},"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527776,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"sale","planned":true,"acquired":false,"shares":847,"price":76.0743,"value":64434.9321,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.995 to $76.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":174854,"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527775,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"sale","planned":true,"acquired":false,"shares":17238,"price":75.4868,"value":1301241.4584,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.985 to $75.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":175701,"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527774,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"sale","planned":true,"acquired":false,"shares":45570,"price":74.4447,"value":3392444.979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":192939,"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527773,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"sale","planned":true,"acquired":false,"shares":3101,"price":73.4881,"value":227886.5981,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":238509,"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527772,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":4.88,"value":146400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."}],"balance_after":241610,"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1527771,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-05-03T20:51:05.000Z","date":"2024-05-03","kind":"exercise","planned":true,"acquired":true,"shares":4249,"price":4.68,"value":19885.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024."}],"balance_after":211610,"source":{"system":"sec-edgar","filing":"0001209191-24-005522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005522/doc4.xml","form_type":"4"}},{"id":1559392,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-03-27T20:50:55.000Z","date":"2024-03-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":16610,"price":83.34,"value":1384277.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon\nthe vesting of certain shares of common stock subject to certain performance restricted stock units."}],"balance_after":207361,"source":{"system":"sec-edgar","filing":"0001209191-24-005116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005116/doc4.xml","form_type":"4"}},{"id":1559391,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-03-27T20:50:55.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal."}],"balance_after":223971,"source":{"system":"sec-edgar","filing":"0001209191-24-005116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124005116/doc4.xml","form_type":"4"}},{"id":1602681,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-03-04T19:50:08.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":20093,"price":85.22,"value":1712325.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon\nthe vesting of certain shares of common stock subject to certain performance restricted stock units."}],"balance_after":192304,"source":{"system":"sec-edgar","filing":"0001209191-24-004231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124004231/doc4.xml","form_type":"4"}},{"id":1602680,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-03-04T19:50:08.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 1, 2024 upon the achievement of a non-financial performance goal."}],"balance_after":212397,"source":{"system":"sec-edgar","filing":"0001209191-24-004231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124004231/doc4.xml","form_type":"4"}},{"id":1687413,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":155000,"derivative":{"exercise_price":17.4,"exercise_date":"2025-01-03","expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1687412,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":17.9,"value":268500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price."}],"balance_after":180730,"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1687411,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":13872,"price":18.58,"value":257741.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units."}],"balance_after":195730,"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1687410,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":30889,"price":17.4,"value":537468.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units."}],"balance_after":209602,"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1687409,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."}],"balance_after":240491,"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1687408,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":18233,"price":17.4,"value":317254.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon\nthe vesting of certain shares of common stock subject to certain performance restricted stock units."}],"balance_after":170491,"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1687407,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-04T21:35:45.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":28334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan."}],"balance_after":188724,"source":{"system":"sec-edgar","filing":"0001209191-24-000929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919124000929/doc4.xml","form_type":"4"}},{"id":1917969,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-18T19:07:10.000Z","date":"2023-04-17","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the shares subject to the option vested on the grant date and one-third of the shares subject to the option vested on each one year anniversary of the grant date of\nAugust 31, 2018."}],"balance_after":0,"derivative":{"exercise_price":13.07,"exercise_date":"2018-08-31","expiration_date":"2028-08-31","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-23-024722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024722/doc4.xml","form_type":"4"}},{"id":1917968,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-18T19:07:10.000Z","date":"2023-04-17","kind":"sale","planned":false,"acquired":false,"shares":7500,"price":20,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":149279,"source":{"system":"sec-edgar","filing":"0001209191-23-024722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024722/doc4.xml","form_type":"4"}},{"id":1917967,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-18T19:07:10.000Z","date":"2023-04-17","kind":"exercise","planned":false,"acquired":true,"shares":7500,"price":13.07,"value":98025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":156779,"source":{"system":"sec-edgar","filing":"0001209191-23-024722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024722/doc4.xml","form_type":"4"}},{"id":1920263,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":4097,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":12750,"derivative":{"exercise_price":7.77,"exercise_date":"2021-01-03","expiration_date":"2030-01-03","underlying":"Common Stock","underlying_shares":4097},"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920262,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":37447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":26000,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":37447},"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920261,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":false,"shares":14553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":63447,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":14553},"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920260,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":90000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920259,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date."}],"balance_after":8500,"derivative":{"exercise_price":4.68,"exercise_date":"2021-03-31","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920258,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":false,"shares":3242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4."}],"balance_after":16847,"derivative":{"exercise_price":7.77,"exercise_date":"2021-01-03","expiration_date":"2030-01-03","underlying":"Common Stock","underlying_shares":3242},"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920257,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":41544,"price":18,"value":747792.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":149279,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920256,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":4097,"price":7.77,"value":31833.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":190823,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920255,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":37447,"price":5.8,"value":217192.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":186726,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920254,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"sale","planned":false,"acquired":false,"shares":56295,"price":18.0037,"value":1013518.2915,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":149279,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920253,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":true,"shares":14553,"price":5.8,"value":84407.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":205574,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920252,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":4.88,"value":146400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":191021,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920251,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":4.68,"value":39780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":161021,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1920250,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-13T17:13:18.000Z","date":"2023-04-11","kind":"exercise","planned":false,"acquired":true,"shares":3242,"price":7.77,"value":25190.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":152521,"source":{"system":"sec-edgar","filing":"0001209191-23-024227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123024227/doc4.xml","form_type":"4"}},{"id":1932143,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-03T19:24:41.000Z","date":"2023-04-03","kind":"exercise","planned":false,"acquired":false,"shares":30911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on each one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":7.77,"exercise_date":"2021-01-03","expiration_date":"2030-01-03","underlying":"Common Stock","underlying_shares":30911},"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932142,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":4.12,"exercise_date":"2018-04-30","expiration_date":"2028-04-30","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932141,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":false,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on each one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":4.65,"exercise_date":"2019-01-19","expiration_date":"2028-01-19","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932140,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-third of the shares subject to the option vested on each one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":7.69,"exercise_date":"2020-07-31","expiration_date":"2029-07-31","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932139,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":false,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vested on each one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":8.52,"exercise_date":"2020-01-15","expiration_date":"2029-01-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932138,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-04-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":55166,"price":17.57,"value":969266.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain  shares of common stock subject to certain performance restricted stock units."}],"balance_after":149279,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932137,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":56667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals."}],"balance_after":204445,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932136,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-04-03","kind":"sale","planned":false,"acquired":false,"shares":30911,"price":18,"value":556398.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":147778,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932135,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-04-03","kind":"exercise","planned":false,"acquired":true,"shares":30911,"price":7.77,"value":240178.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":178689,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932134,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"sale","planned":false,"acquired":false,"shares":131029,"price":17.0025,"value":2227820.5725,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":147778,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932133,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":true,"shares":7500,"price":4.12,"value":30900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":278807,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932132,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":true,"shares":12250,"price":4.65,"value":56962.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":271307,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932131,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":true,"shares":42000,"price":7.69,"value":322980.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":259057,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":1932130,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-04-03T19:24:41.000Z","date":"2023-03-30","kind":"exercise","planned":false,"acquired":true,"shares":32000,"price":8.52,"value":272640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":217057,"source":{"system":"sec-edgar","filing":"0001209191-23-022398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123022398/doc4.xml","form_type":"4"}},{"id":2066518,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T18:25:50.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":204000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":204000,"derivative":{"exercise_price":8.52,"exercise_date":"2024-01-03","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":204000},"source":{"system":"sec-edgar","filing":"0001209191-23-001343","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123001343/doc4.xml","form_type":"4"}},{"id":2066517,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-01-04T18:25:50.000Z","date":"2023-01-04","kind":"tax_withholding","acquired":false,"shares":20708,"price":8.42,"value":174361.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units."}],"balance_after":185057,"source":{"system":"sec-edgar","filing":"0001209191-23-001343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123001343/doc4.xml","form_type":"4"}},{"id":2066516,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-01-04T18:25:50.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":23933,"price":8.52,"value":203909.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units."}],"balance_after":205765,"source":{"system":"sec-edgar","filing":"0001209191-23-001343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123001343/doc4.xml","form_type":"4"}},{"id":2066515,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-01-04T18:25:50.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":90667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."}],"balance_after":229698,"source":{"system":"sec-edgar","filing":"0001209191-23-001343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123001343/doc4.xml","form_type":"4"}},{"id":2066514,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-01-04T18:25:50.000Z","date":"2022-12-30","kind":"tax_withholding","acquired":false,"shares":19697,"price":9.4,"value":185151.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units."}],"balance_after":139031,"source":{"system":"sec-edgar","filing":"0001209191-23-001343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123001343/doc4.xml","form_type":"4"}},{"id":2066513,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-01-04T18:25:50.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":20233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,080 shares acquired on May 20, 2022 and 1,111 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan."}],"balance_after":158728,"source":{"system":"sec-edgar","filing":"0001209191-23-001343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919123001343/doc4.xml","form_type":"4"}},{"id":2443366,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T19:13:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":120000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-22-001988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919122001988/doc4.xml","form_type":"4"}},{"id":2443365,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2022-01-05T19:13:27.000Z","date":"2022-01-04","kind":"tax_withholding","acquired":false,"shares":8835,"price":4.62,"value":40817.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units."}],"balance_after":136304,"source":{"system":"sec-edgar","filing":"0001209191-22-001988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919122001988/doc4.xml","form_type":"4"}},{"id":2443364,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2022-01-05T19:13:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":53333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date."}],"balance_after":145139,"source":{"system":"sec-edgar","filing":"0001209191-22-001988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919122001988/doc4.xml","form_type":"4"}},{"id":2443363,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2022-01-05T19:13:27.000Z","date":"2022-01-03","kind":"tax_withholding","acquired":false,"shares":3097,"price":4.88,"value":15113.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 418 shares acquired on November 19, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan."}],"balance_after":91806,"source":{"system":"sec-edgar","filing":"0001209191-22-001988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919122001988/doc4.xml","form_type":"4"}},{"id":2555694,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2021-09-30T17:43:38.000Z","date":"2021-09-28","kind":"tax_withholding","acquired":false,"shares":2306,"price":6.5,"value":14989.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award."}],"balance_after":94485,"source":{"system":"sec-edgar","filing":"0001209191-21-058246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000120919121058246/doc4.xml","form_type":"4"}}],"next_cursor":"2021-09-30T17:43:38.000000Z,2555694"}